Vsevolod Gennadevich Potapenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vsevolod Gennadevich Potapenko has a total of 353 co-authors. Here are the top co-authors by number of shared publications:
- Nadezhda V. Medvedeva
City Clinical Hospital No. 31, 3 Dinamo pr-t, Saint Petersburg, Russian Federation, 197110
9 shared publications - Vadim V. Baykov
RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022
8 shared publications - Tatiana G. Kulibaba
Saint-Petersburg State University
7 shared publications - Victoria V. Ryabchikova
City Clinical Hospital No. 31
7 shared publications - Margarita Yu. Pervakova
НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
6 shared publications - Sergey Vladimirovich Lapin
First Pavlov State Medical University of St. Petersburg
6 shared publications
Latest Publications
- 30 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (5) , 357-366
Secondary haemophagocytic lymphohistiocytosis in blood malignancies. The multicentre retrospective study
Haemophagocytic syndrome (HPS) or haemophagocytic lymphohistiocytosis is a reaction of severe but ineffective inflammation. Blood malignancies (BlM) are among the frequent causes of HPS in adults. Objective. To analyse survival, causing trigger haemoblastosis, relationship with tumor and efficacy of including etoposide in chemotherapy of patients with secondary HPS-BlM. Material and methods. A retrospective analysis of case histories of patients with BlM complicated by SHPS was performed. The diagnosis of SHPS was verified using H-score and HLH-2004 criteria. Patients with both active malignant process and response to treatment were included in the study. Results. A total of 66 patients, median age 64 (19–90) years, 26 males and 40 females were included in the analysis. Of these, 44 (66.7%) had an active malignant process present. Overall survival in the SHPS-BlM group was 15.1% with a median of 2 (0.2–150) weeks. The prognosis was better in the group treated with etoposide than without it: three-week overall survival was 65.6% (n = 9) and 35%, respectively (p = 0.023). Median survival in the etoposide-free group was 1 (0.2–140) weeks. There were no diff erences in long-term survival depending on the presence of etoposide as part of chemotherapy. In patients without malignancy progression, a possible cause of SHPS was identified in only 8 (36.3%) patients. The overall survival rate was 18.1%, median 12 days (from 3 days to 150 weeks). Conclusion. The structure of patients with SHPS-BlM is dominated by patients with diff use B-cell large cell lymphoma. In the majority of patients SHPS is associated with progression, but in some patients VGFS activity persists despite the achievement of antitumour response. Inclusion of etoposide in therapy leads to an improved prognosis.
- 30 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (5) , 357-366
Secondary haemophagocytic lymphohistiocytosis in blood malignancies. The multicentre retrospective study
Haemophagocytic syndrome (HPS) or haemophagocytic lymphohistiocytosis is a reaction of severe but ineffective inflammation. Blood malignancies (BlM) are among the frequent causes of HPS in adults. Objective. To analyse survival, causing trigger haemoblastosis, relationship with tumor and efficacy of including etoposide in chemotherapy of patients with secondary HPS-BlM. Material and methods. A retrospective analysis of case histories of patients with BlM complicated by SHPS was performed. The diagnosis of SHPS was verified using H-score and HLH-2004 criteria. Patients with both active malignant process and response to treatment were included in the study. Results. A total of 66 patients, median age 64 (19–90) years, 26 males and 40 females were included in the analysis. Of these, 44 (66.7%) had an active malignant process present. Overall survival in the SHPS-BlM group was 15.1% with a median of 2 (0.2–150) weeks. The prognosis was better in the group treated with etoposide than without it: three-week overall survival was 65.6% (n = 9) and 35%, respectively (p = 0.023). Median survival in the etoposide-free group was 1 (0.2–140) weeks. There were no diff erences in long-term survival depending on the presence of etoposide as part of chemotherapy. In patients without malignancy progression, a possible cause of SHPS was identified in only 8 (36.3%) patients. The overall survival rate was 18.1%, median 12 days (from 3 days to 150 weeks). Conclusion. The structure of patients with SHPS-BlM is dominated by patients with diff use B-cell large cell lymphoma. In the majority of patients SHPS is associated with progression, but in some patients VGFS activity persists despite the achievement of antitumour response. Inclusion of etoposide in therapy leads to an improved prognosis.
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Efficacy and Safety of Various Treatment Regimens for Primary CNS Lymphoma: Results of a Retrospective Study Based on the Data from Nine Saint Petersburg Medical Institutions
BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessEfficacy and Safety of Various Treatment Regimens for Primary CNS Lymphoma: Results of a Retrospective Study Based on the Data from Nine Saint Petersburg Medical Institutions
BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.
- Open Access
- 1 January 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (1)
Expert Review on the Quality of Responses to the Questions of Multiple Myeloma Patients: A Validation Study of the Medical Artificial Intelligence System “Myelobot”
BACKGROUND. The use of artificial intelligence (AI) in oncology and hematology opens up many possibilities for improving health service systems including communication between physicians and patients with long-standing diseases, such as multiple myeloma (MM). Generative AI based on the large language models is increasingly introduced into clinical practice. However, the issues of the quality of information provided as well as the level of empathy and clinical safety of such systems have until now remained underresearched. AIM. A comprehensive prospective evaluation of the quality of responses to the questions of MM patients provided by the specialized medical AI system “Myelobot”. MATERIALS & METHODS. This study used the scores of accuracy, empathy, and potential harm and additionally analyzed the consistency in reviewers’ ratings. All scores were measured with 5-point Likert scale with lower points corresponding to higher quality, safety, and empathy level of responses. Three hematologists participated in the study, independently and anonymously reviewing 32 AI system responses to patient questions across three scores. RESULTS. The median values of all scores appeared to be significantly lower than empirical threshold of 2.5 points (p < 0.001), suggesting a high quality of responses. At the same time, the Fleiss kappa and Krippendorff alpha coefficients of consistency in reviewers’ ratings were negative, especially on the empathy score, suggesting substantial variability in expert evaluations. CONCLUSION. AI service “Myelobot” demonstrated a high level of accuracy, clinical safety, and ability for empathic communication with MM patients. However, conflicting expert ratings clearly indicate the need for standardization of the scores and calibration of evaluation approaches in future studies. According to medical specialists, AI service system “Myelobot” is a highly effective MM patient support tool with a capacity to carry out the function of physician assistant providing medical information 24 hours a day.
- 1 January 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (1)
Open AccessExpert Review on the Quality of Responses to the Questions of Multiple Myeloma Patients: A Validation Study of the Medical Artificial Intelligence System “Myelobot”
BACKGROUND. The use of artificial intelligence (AI) in oncology and hematology opens up many possibilities for improving health service systems including communication between physicians and patients with long-standing diseases, such as multiple myeloma (MM). Generative AI based on the large language models is increasingly introduced into clinical practice. However, the issues of the quality of information provided as well as the level of empathy and clinical safety of such systems have until now remained underresearched. AIM. A comprehensive prospective evaluation of the quality of responses to the questions of MM patients provided by the specialized medical AI system “Myelobot”. MATERIALS & METHODS. This study used the scores of accuracy, empathy, and potential harm and additionally analyzed the consistency in reviewers’ ratings. All scores were measured with 5-point Likert scale with lower points corresponding to higher quality, safety, and empathy level of responses. Three hematologists participated in the study, independently and anonymously reviewing 32 AI system responses to patient questions across three scores. RESULTS. The median values of all scores appeared to be significantly lower than empirical threshold of 2.5 points (p < 0.001), suggesting a high quality of responses. At the same time, the Fleiss kappa and Krippendorff alpha coefficients of consistency in reviewers’ ratings were negative, especially on the empathy score, suggesting substantial variability in expert evaluations. CONCLUSION. AI service “Myelobot” demonstrated a high level of accuracy, clinical safety, and ability for empathic communication with MM patients. However, conflicting expert ratings clearly indicate the need for standardization of the scores and calibration of evaluation approaches in future studies. According to medical specialists, AI service system “Myelobot” is a highly effective MM patient support tool with a capacity to carry out the function of physician assistant providing medical information 24 hours a day.
- Open Access
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 355-371
Возможности терапии хронической активной болезни и вторичного гемофагоцитарного синдрома, ассоциированных с вирусом Эпштейна—Барр (серия клинических наблюдений)
Epstein-Barr virus (EBV) infection is characterized by a benign course except for the rare variants which include chronic active disease (EBV-CAD) and secondary hemophagocytic syndrome (EBV-sHPS). sHPS is a life-threatening disorder associated with severely impaired immune response regulation. The pathogenesis is based on the activation of cytotoxic Т-lymphocytes, NK-cells and macrophages with overproduction of proinflammatory cytokines and ineffective systemic inflammatory response. The most common manifestations are persistent febrile fever, moderate cytopenia, cytolytic and cholestatic syndromes, and multiple organ failure. One of the most effective agents for the control of hyperergic reaction is etoposide. The present paper reports the outcomes of treating 5 EBV-sHPS patients and 1 EBV-CAD patient. All of them showed fever, liver dysfunction, hypofibrinogenemia, and cytopenia. In sHPS patients, pronounced hyperferritinemia was identified. At the time of submitting the present paper, 3 patients with no evident disease were still followed up.
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 355-371
Open AccessВозможности терапии хронической активной болезни и вторичного гемофагоцитарного синдрома, ассоциированных с вирусом Эпштейна—Барр (серия клинических наблюдений)
Epstein-Barr virus (EBV) infection is characterized by a benign course except for the rare variants which include chronic active disease (EBV-CAD) and secondary hemophagocytic syndrome (EBV-sHPS). sHPS is a life-threatening disorder associated with severely impaired immune response regulation. The pathogenesis is based on the activation of cytotoxic Т-lymphocytes, NK-cells and macrophages with overproduction of proinflammatory cytokines and ineffective systemic inflammatory response. The most common manifestations are persistent febrile fever, moderate cytopenia, cytolytic and cholestatic syndromes, and multiple organ failure. One of the most effective agents for the control of hyperergic reaction is etoposide. The present paper reports the outcomes of treating 5 EBV-sHPS patients and 1 EBV-CAD patient. All of them showed fever, liver dysfunction, hypofibrinogenemia, and cytopenia. In sHPS patients, pronounced hyperferritinemia was identified. At the time of submitting the present paper, 3 patients with no evident disease were still followed up.
- Open Access
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 286-292
Epstein-Barr Virus-Associated Secondary Hemophagocytic Syndrome and Chronic Active Disease: A Literature Review
Epstein-Barr virus (EBV) infection can cause secondary hemophagocytic syndrome and severe chronic active disease. The diseases are characterized by pathologic hyperergic reaction manifested by fever, cytopenia, and multiple organ failure. Cytostatic therapy reduces inflammatory response, allows for infection resolution, or stabilizes the patient before the next stage of treatment. This paper reviews current knowledge about diagnosis and treatment of EBV-associated diseases with the main focus on chemotherapy for EBV-associated secondary hemophagocytic syndrome and chronic active disease.
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 286-292
Open AccessEpstein-Barr Virus-Associated Secondary Hemophagocytic Syndrome and Chronic Active Disease: A Literature Review
Epstein-Barr virus (EBV) infection can cause secondary hemophagocytic syndrome and severe chronic active disease. The diseases are characterized by pathologic hyperergic reaction manifested by fever, cytopenia, and multiple organ failure. Cytostatic therapy reduces inflammatory response, allows for infection resolution, or stabilizes the patient before the next stage of treatment. This paper reviews current knowledge about diagnosis and treatment of EBV-associated diseases with the main focus on chemotherapy for EBV-associated secondary hemophagocytic syndrome and chronic active disease.
- Open Access
- 28 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 423-441-441
Treatment of secondary hemophagocytic syndrome
Introduction. Hemophagocytic syndrome (HPS) is a reaction of severe, excessive, but ineffective inflammation. HPS is divided into primary or as a complication of a different causes — secondary HPS (sHPS).Aim: to analyze the effi cacy of different treatments in sHPS patients.Materials and methods. For the retrospective analysis, the medical documentation of patients who were treated in the period from June 2009 to January 2023 was used. The H-Score and HLH-2004 criteria were used to verify sHPS. The results of clinical blood analysis and biochemical tests are presented. The survival was analyzed within two weeks after the verification of sHPS. The main treatment options for sHPS were etoposide, glucocorticosteroids (GCSs), anticancer therapy and intravenous immunoglobulin.Results. The study included data from 130 patients, median age 56 years (18–90); 70 females and 60 males with sHPS. All patients received treatment with a drug change in cases of inefficiency: a total of 186 episodes. A stable response was achieved in 74 (56.9 %) patients. The median survival in patients without a response was 2 days. If the therapy was effective, the median survival was not reached. Positive dynamics were observed during the first day after the start of effective treatment, however, a few patients had transient worsening of some markers. The main factor in the negative prognosis was the degree of multiple organ failure during sHPS verification. In the group of patients with autoimmune diseases, GCSs were the most effective, with a response reached in 75 % of cases. For patients with resistance, as well as in patients with Epstein—Barr virus infection and blood malignancy, etoposide proved to be effective in 65.7 % of cases.Conclusion. sHPS was accompanied by an increase in pancytopenia, cytolytic, cholestatic syndromes, hypocoagulation, azotemia, hypertriglyceridemia and excessive hyperferritinemia. After the initiation of effective therapy, persistent clinical and laboratory responses developed during the first day. Therapy by GCSs was effective in most patients with autoimmune diseases associated with sHPS. With other forms of sHPS in the studied group, etoposide had the most pronounced effect.
- 28 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 423-441-441
Open AccessTreatment of secondary hemophagocytic syndrome
Introduction. Hemophagocytic syndrome (HPS) is a reaction of severe, excessive, but ineffective inflammation. HPS is divided into primary or as a complication of a different causes — secondary HPS (sHPS).Aim: to analyze the effi cacy of different treatments in sHPS patients.Materials and methods. For the retrospective analysis, the medical documentation of patients who were treated in the period from June 2009 to January 2023 was used. The H-Score and HLH-2004 criteria were used to verify sHPS. The results of clinical blood analysis and biochemical tests are presented. The survival was analyzed within two weeks after the verification of sHPS. The main treatment options for sHPS were etoposide, glucocorticosteroids (GCSs), anticancer therapy and intravenous immunoglobulin.Results. The study included data from 130 patients, median age 56 years (18–90); 70 females and 60 males with sHPS. All patients received treatment with a drug change in cases of inefficiency: a total of 186 episodes. A stable response was achieved in 74 (56.9 %) patients. The median survival in patients without a response was 2 days. If the therapy was effective, the median survival was not reached. Positive dynamics were observed during the first day after the start of effective treatment, however, a few patients had transient worsening of some markers. The main factor in the negative prognosis was the degree of multiple organ failure during sHPS verification. In the group of patients with autoimmune diseases, GCSs were the most effective, with a response reached in 75 % of cases. For patients with resistance, as well as in patients with Epstein—Barr virus infection and blood malignancy, etoposide proved to be effective in 65.7 % of cases.Conclusion. sHPS was accompanied by an increase in pancytopenia, cytolytic, cholestatic syndromes, hypocoagulation, azotemia, hypertriglyceridemia and excessive hyperferritinemia. After the initiation of effective therapy, persistent clinical and laboratory responses developed during the first day. Therapy by GCSs was effective in most patients with autoimmune diseases associated with sHPS. With other forms of sHPS in the studied group, etoposide had the most pronounced effect.
- Open Access
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3)
Cladribine in the Treatment of Multifocal Multisystem Langerhans Cell Histiocytosis in a Patient with a Poor Prognosis. A Case Report
Langerhans cell histiocytosis is a hematologic clonal disease. The treatment of localized histiocytosis includes local methods such as radiotherapy or surgery. In cases of disseminated lesions with multiple system damage, chemotherapy is administered, which provides recovery in some patients. The present paper is a case report of multifocal multisystem Langerhans cell histiocytosis with bone, liver, spleen, abdominal lymph node and pituitary lesions in a 40-year-old patient. The diagnosis was verified by histology and immunohistochemistry of bone biopsy specimens. Polymerase chain reaction revealed no V600E mutation in the BRAF gene in tumor tissue. Persistent antitumor response was achieved after 6 chemotherapy cycles with cladribine monoregimen. This drug was well tolerated by the patient. By the time of this publication, the patient had preserved the persistent response for 38 months.
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3)
Open AccessCladribine in the Treatment of Multifocal Multisystem Langerhans Cell Histiocytosis in a Patient with a Poor Prognosis. A Case Report
Langerhans cell histiocytosis is a hematologic clonal disease. The treatment of localized histiocytosis includes local methods such as radiotherapy or surgery. In cases of disseminated lesions with multiple system damage, chemotherapy is administered, which provides recovery in some patients. The present paper is a case report of multifocal multisystem Langerhans cell histiocytosis with bone, liver, spleen, abdominal lymph node and pituitary lesions in a 40-year-old patient. The diagnosis was verified by histology and immunohistochemistry of bone biopsy specimens. Polymerase chain reaction revealed no V600E mutation in the BRAF gene in tumor tissue. Persistent antitumor response was achieved after 6 chemotherapy cycles with cladribine monoregimen. This drug was well tolerated by the patient. By the time of this publication, the patient had preserved the persistent response for 38 months.
- Open Access
- 3 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 46-55
Cladribine chemotherapy of multifocal, multisystemic form of Rosai–Dorfman disease: literature review and case report
Rosai–Dorfman disease is the most frequent variant of non-Langerhans cell histiocytosis. Local forms can be resected or irradiated. If the process involves multiple organs, systemic chemotherapy can cure some patients. This article includes literature review and a case report of a 34-year-old patient with multifocal, multisystemic form of Rosai–Dorfman disease with bone and pleural involvement. The diagnosis was based on histological, immunohistochemical, and molecular studies of tumor tissue. Since November 2021, 6 courses of chemotherapy with cladribine and 8 infusions of zolendronic acid were carried out with achievement of durable remission. The tolerance was acceptable.
- 3 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 46-55
Open AccessCladribine chemotherapy of multifocal, multisystemic form of Rosai–Dorfman disease: literature review and case report
Rosai–Dorfman disease is the most frequent variant of non-Langerhans cell histiocytosis. Local forms can be resected or irradiated. If the process involves multiple organs, systemic chemotherapy can cure some patients. This article includes literature review and a case report of a 34-year-old patient with multifocal, multisystemic form of Rosai–Dorfman disease with bone and pleural involvement. The diagnosis was based on histological, immunohistochemical, and molecular studies of tumor tissue. Since November 2021, 6 courses of chemotherapy with cladribine and 8 infusions of zolendronic acid were carried out with achievement of durable remission. The tolerance was acceptable.
- Open Access
- 1 April 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (2) , 180-194
Treatment of Aggressive Systemic Mastocytosis and Mast Cell Leukemia. Literature Review and Case Reports
Aim. To provide case reports on the course and treatment of aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). Materials & Methods. This paper reports the histories of adult patients with ASM (n = 4) and MCL (n = 2) treated with cytoreduction predominantly at the City Clinical Hospital No. 31 (Saint Petersburg). The patients were 36–61 years of age (median 50 years); there were 4 women and 2 men. Results. All patients showed stable response to cladribine (n = 3), imatinib (n = 2), and combined lenalidomide, elotuzumab, and dexamethasone treatment with subsequent allogeneic hematopoietic stem cell transplantation (n = 1). With a median follow-up of 124 months (range 55–186 months), 1 out of 2 MCL patients died due to the concomitant hypereosinophilic syndrome progression and secondary infectious complication. Conclusion. Cladribine therapy in 2 ASM patients and imatinib therapy in 2 MCL patients yielded stable long-term response with good quality of life being maintained. More comparative studies are required for efficacy assessment and optimum sequencing of chemotherapeutic drugs.
- 1 April 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (2) , 180-194
Open AccessTreatment of Aggressive Systemic Mastocytosis and Mast Cell Leukemia. Literature Review and Case Reports
Aim. To provide case reports on the course and treatment of aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). Materials & Methods. This paper reports the histories of adult patients with ASM (n = 4) and MCL (n = 2) treated with cytoreduction predominantly at the City Clinical Hospital No. 31 (Saint Petersburg). The patients were 36–61 years of age (median 50 years); there were 4 women and 2 men. Results. All patients showed stable response to cladribine (n = 3), imatinib (n = 2), and combined lenalidomide, elotuzumab, and dexamethasone treatment with subsequent allogeneic hematopoietic stem cell transplantation (n = 1). With a median follow-up of 124 months (range 55–186 months), 1 out of 2 MCL patients died due to the concomitant hypereosinophilic syndrome progression and secondary infectious complication. Conclusion. Cladribine therapy in 2 ASM patients and imatinib therapy in 2 MCL patients yielded stable long-term response with good quality of life being maintained. More comparative studies are required for efficacy assessment and optimum sequencing of chemotherapeutic drugs.
- Open Access
- 27 December 2022
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 68 (6) , 786-796
Burkitt lymphoma in patients with HIV infection: results of a Russian multicenter study
Введение. Лимфома Беркитта (ЛБ) ― высокоагрессивная В-клеточная неходжкинская лимфома, составляет до 40% лимфом у пациентов с ВИЧ-инфекцией. Широкое применение антиретровирусной терапии (АРВТ) способствовало улучшению результатов противоопухолевой химиотерапии (ПХТ) лимфом на фоне ВИЧ-инфекции, в том числе ЛБ. Терапии ЛБ в РФ посвящено только несколько работ, а публикаций о ЛБ у пациентов с ВИЧ-инфекцией нет. Цель работы: изучить клинико-эпидемиологические характеристики и оценить результаты терапии ЛБ у пациентов с ВИЧ-инфекцией в РФ. Материалы и методы. В исследование было включено 37 пациентов с ЛБ на фоне ВИЧ-инфекции, проходивших лечение в 10 центрах РФ в период с 2010 по 2021 гг. Результаты. ЛБ у пациентов с ВИЧ-инфекцией диагностируется в молодом возрасте, с медианой 37 лет (21–58 лет), чаще у мужчин (75,7%), в распространенной стадии (IV стадия Ann Arbor ― 64,7%) и с экстралимфатическими проявлениями (73,5%), включая поражение центральной нервной системы (ЦНС) (16,1%). Основная терапия: EPOCH-подобные курсы (54,1%), блоковые схемы (32,4%). У 76% пациентов противоопухолевая ХТ включала ритуксимаб, у 91,4% ― одновременно с АРВТ. Медиана количества курсов терапии составила 4 (1–8). Общая выживаемость (ОВ) в течение 1 года составила 64% (95% ДИ 38–82%), выживаемость без прогрессирования (ВБП) ― 59% (95% ДИ 34–77%). Поражение ЦНС (p=0.0064), и проведение ПХТ без АРВТ ухудшает ОВ (p=0,00016) и ВБП (p=0,00012). Заключение. Для улучшения результатов терапии и прогноза необходимы проспективные м Введение. Лимфома Беркитта (ЛБ) ― высокоагрессивная В-клеточная неходжкинская лимфома, составляет до 40% лимфом у пациентов с ВИЧ-инфекцией. Широкое применение антиретровирусной терапии (АРВТ) способствовало улучшению результатов противоопухолевой химиотерапии (ПХТ) лимфом на фоне ВИЧ-инфекции, в том числе ЛБ. Терапии ЛБ в РФ посвящено только несколько работ, а публикаций о ЛБ у пациентов с ВИЧ-инфекцией нет. Цель работы: изучить клинико-эпидемиологические характеристики и оценить результаты терапии ЛБ у пациентов с ВИЧ-инфекцией в РФ. Материалы и методы. В исследование было включено 37 пациентов с ЛБ на фоне ВИЧ-инфекции, проходивших лечение в 10 центрах РФ в период с 2010 по 2021 гг. Результаты. ЛБ у пациентов с ВИЧ-инфекцией диагностируется в молодом возрасте, с медианой 37 лет (21–58 лет), чаще у мужчин (75,7%), в распространенной стадии (IV стадия Ann Arbor ― 64,7%) и с экстралимфатическими проявлениями (73,5%), включая поражение центральной нервной системы (ЦНС) (16,1%). Основная терапия: EPOCH-подобные курсы (54,1%), блоковые схемы (32,4%). У 76% пациентов противоопухолевая ХТ включала ритуксимаб, у 91,4% ― одновременно с АРВТ. Медиана количества курсов терапии составила 4 (1–8). Общая выживаемость (ОВ) в течение 1 года составила 64% (95% ДИ 38–82%), выживаемость без прогрессирования (ВБП) ― 59% (95% ДИ 34–77%). Поражение ЦНС (p=0.0064), и проведение ПХТ без АРВТ ухудшает ОВ (p=0,00016) и ВБП (p=0,00012). Заключение. Для улучшения результатов терапии и прогноза необходимы проспективные многоцентровые исследования по лечению ЛБ у пациентов с ВИЧ. ногоцентровые исследования по лечению ЛБ у пациентов с ВИЧ.
- 27 December 2022
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 68 (6) , 786-796
Open AccessBurkitt lymphoma in patients with HIV infection: results of a Russian multicenter study
Введение. Лимфома Беркитта (ЛБ) ― высокоагрессивная В-клеточная неходжкинская лимфома, составляет до 40% лимфом у пациентов с ВИЧ-инфекцией. Широкое применение антиретровирусной терапии (АРВТ) способствовало улучшению результатов противоопухолевой химиотерапии (ПХТ) лимфом на фоне ВИЧ-инфекции, в том числе ЛБ. Терапии ЛБ в РФ посвящено только несколько работ, а публикаций о ЛБ у пациентов с ВИЧ-инфекцией нет. Цель работы: изучить клинико-эпидемиологические характеристики и оценить результаты терапии ЛБ у пациентов с ВИЧ-инфекцией в РФ. Материалы и методы. В исследование было включено 37 пациентов с ЛБ на фоне ВИЧ-инфекции, проходивших лечение в 10 центрах РФ в период с 2010 по 2021 гг. Результаты. ЛБ у пациентов с ВИЧ-инфекцией диагностируется в молодом возрасте, с медианой 37 лет (21–58 лет), чаще у мужчин (75,7%), в распространенной стадии (IV стадия Ann Arbor ― 64,7%) и с экстралимфатическими проявлениями (73,5%), включая поражение центральной нервной системы (ЦНС) (16,1%). Основная терапия: EPOCH-подобные курсы (54,1%), блоковые схемы (32,4%). У 76% пациентов противоопухолевая ХТ включала ритуксимаб, у 91,4% ― одновременно с АРВТ. Медиана количества курсов терапии составила 4 (1–8). Общая выживаемость (ОВ) в течение 1 года составила 64% (95% ДИ 38–82%), выживаемость без прогрессирования (ВБП) ― 59% (95% ДИ 34–77%). Поражение ЦНС (p=0.0064), и проведение ПХТ без АРВТ ухудшает ОВ (p=0,00016) и ВБП (p=0,00012). Заключение. Для улучшения результатов терапии и прогноза необходимы проспективные м Введение. Лимфома Беркитта (ЛБ) ― высокоагрессивная В-клеточная неходжкинская лимфома, составляет до 40% лимфом у пациентов с ВИЧ-инфекцией. Широкое применение антиретровирусной терапии (АРВТ) способствовало улучшению результатов противоопухолевой химиотерапии (ПХТ) лимфом на фоне ВИЧ-инфекции, в том числе ЛБ. Терапии ЛБ в РФ посвящено только несколько работ, а публикаций о ЛБ у пациентов с ВИЧ-инфекцией нет. Цель работы: изучить клинико-эпидемиологические характеристики и оценить результаты терапии ЛБ у пациентов с ВИЧ-инфекцией в РФ. Материалы и методы. В исследование было включено 37 пациентов с ЛБ на фоне ВИЧ-инфекции, проходивших лечение в 10 центрах РФ в период с 2010 по 2021 гг. Результаты. ЛБ у пациентов с ВИЧ-инфекцией диагностируется в молодом возрасте, с медианой 37 лет (21–58 лет), чаще у мужчин (75,7%), в распространенной стадии (IV стадия Ann Arbor ― 64,7%) и с экстралимфатическими проявлениями (73,5%), включая поражение центральной нервной системы (ЦНС) (16,1%). Основная терапия: EPOCH-подобные курсы (54,1%), блоковые схемы (32,4%). У 76% пациентов противоопухолевая ХТ включала ритуксимаб, у 91,4% ― одновременно с АРВТ. Медиана количества курсов терапии составила 4 (1–8). Общая выживаемость (ОВ) в течение 1 года составила 64% (95% ДИ 38–82%), выживаемость без прогрессирования (ВБП) ― 59% (95% ДИ 34–77%). Поражение ЦНС (p=0.0064), и проведение ПХТ без АРВТ ухудшает ОВ (p=0,00016) и ВБП (p=0,00012). Заключение. Для улучшения результатов терапии и прогноза необходимы проспективные многоцентровые исследования по лечению ЛБ у пациентов с ВИЧ. ногоцентровые исследования по лечению ЛБ у пациентов с ВИЧ.